NO20006667L - Retinoid-relaterte reseptor funksjonsregulerende middel - Google Patents

Retinoid-relaterte reseptor funksjonsregulerende middel

Info

Publication number: NO20006667L
Authority: NO; Norway
Prior art keywords: cachexia; hydrocarbon group; insulin; hydrogen; optionally substituted
Prior art date: 1998-07-01

Application number

NO20006667A

Other languages

English (en)

Norwegian (no)

Other versions

NO20006667D0 (no

Inventor

Yasuo Sugiyama

Yu Momose

Hiroyuki Kimura

Junichi Sakamoto

Hiroyuki Odaka

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-01

Filing date

2000-12-27

Publication date

2001-02-28

2000-12-27 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2000-12-27 Publication of NO20006667D0 publication Critical patent/NO20006667D0/no

2001-02-28 Publication of NO20006667L publication Critical patent/NO20006667L/no

Links

150000004492 retinoid derivatives Chemical class 0.000 title 1
206010006895 Cachexia Diseases 0.000 abstract 8
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
208000011580 syndromic disease Diseases 0.000 abstract 4
208000002705 Glucose Intolerance Diseases 0.000 abstract 3
206010012601 diabetes mellitus Diseases 0.000 abstract 3
125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
201000009104 prediabetes syndrome Diseases 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
206010022489 Insulin Resistance Diseases 0.000 abstract 2
125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000017169 kidney disease Diseases 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
208000002249 Diabetes Complications Diseases 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010062016 Immunosuppression Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010054805 Macroangiopathy Diseases 0.000 abstract 1
208000029725 Metabolic bone disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010049088 Osteopenia Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
206010038923 Retinopathy Diseases 0.000 abstract 1
208000020764 Sensation disease Diseases 0.000 abstract 1
208000000453 Skin Neoplasms Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
206010008118 cerebral infarction Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000037406 food intake Effects 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
201000008980 hyperinsulinism Diseases 0.000 abstract 1
230000001631 hypertensive effect Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000009925 nephrosclerosis Diseases 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000849 skin cancer Diseases 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
230000007704 transition Effects 0.000 abstract 1
201000008827 tuberculosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

NO20006667A 1998-07-01 2000-12-27 Retinoid-relaterte reseptor funksjonsregulerende middel NO20006667L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP18669898		1998-07-01
PCT/JP1999/003520 WO2000001679A1 (en)	1998-07-01	1999-06-30	Retinoid-associated receptor regulators

Publications (2)

Publication Number	Publication Date
NO20006667D0 NO20006667D0 (no)	2000-12-27
NO20006667L true NO20006667L (no)	2001-02-28

Family

ID=16193077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006667A NO20006667L (no)	1998-07-01	2000-12-27	Retinoid-relaterte reseptor funksjonsregulerende middel

Country Status (16)

Country	Link
US (1)	US6545009B1 (id)
EP (1)	EP1092711A4 (id)
KR (1)	KR20010053282A (id)
CN (1)	CN1314899A (id)
AU (1)	AU4394799A (id)
BR (1)	BR9911752A (id)
CA (1)	CA2332178A1 (id)
HU (1)	HUP0102470A3 (id)
ID (1)	ID29247A (id)
IL (1)	IL140422A0 (id)
LV (1)	LV12633B (id)
NO (1)	NO20006667L (id)
PL (1)	PL345247A1 (id)
SK (1)	SK20182000A3 (id)
WO (1)	WO2000001679A1 (id)
ZA (1)	ZA200007635B (id)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
AR035016A1 (es)	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1394154A4 (en) *	2001-03-23	2005-05-18	Takeda Pharmaceutical	FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
EP1379259A1 (en) *	2001-04-18	2004-01-14	Genzyme Corporation	Methods of treating syndrome x with aliphatic polyamines
GB0112348D0 (en) *	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
WO2003000301A1 (en) *	2001-06-22	2003-01-03	Merck & Co., Inc.	Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflammation
EP1405636A4 (en) *	2001-06-26	2009-04-15	Takeda Pharmaceutical	FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
JP2003081832A (ja) *	2001-06-26	2003-03-19	Takeda Chem Ind Ltd	レチノイド関連受容体機能調節剤
ES2280596T3 (es) *	2001-12-29	2007-09-16	Novo Nordisk A/S	Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
US7183276B2 (en)	2002-02-28	2007-02-27	Takeda Pharmaceutical Company Limited	Azole compounds
BR0315815A (pt)	2002-11-01	2005-09-13	Takeda Pharmaceutical	Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
GB0303503D0 (en) *	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1856072A4 (en) *	2005-02-25	2009-10-21	Seoul Nat Univ Ind Foundation	THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND PROCESSES FOR THE PRODUCTION THEREOF
JP5191744B2 (ja) *	2005-02-25	2013-05-08	ソウルナショナルユニバーシティーインダストリーファンデーション	ペルオキシソーム増殖子活性化受容体デルタリガンドのチアゾール誘導体及びその製造方法
CA2623327A1 (en) *	2005-10-07	2007-04-19	Kissei Pharmaceutical Co., Ltd.	Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2008064136A2 (en) *	2006-11-17	2008-05-29	Acadia Pharmaceuticals Inc.	Compounds with activity at retinoic acid receptors
US9187485B2 (en)	2007-02-02	2015-11-17	Baylor College Of Medicine	Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9233941B2 (en)	2007-02-02	2016-01-12	Baylor College Of Medicine	Methods and compositions for the treatment of body weight related disorders
EP2120580B1 (en) *	2007-02-02	2017-12-27	Baylor College Of Medicine	Compositions and methods for the treatment of metabolic disorders
US9085566B2 (en)	2007-02-02	2015-07-21	Baylor College Of Medicine	Compositions and methods for the treatment of metabolic and related disorders
US9212179B2 (en)	2007-02-02	2015-12-15	Baylor College Of Medicine	Compositions and methods for the treatment of metabolic disorders
ES2655466T3 (es)	2007-08-13	2018-02-20	Monsanto Technology Llc	Composiciones y procedimientos de control de nematodos
US20120244079A1 (en) *	2009-05-07	2012-09-27	Baylor College Of Medicine	Traceable retinoid acid for imaging, disease prevention and therapy
GB0915196D0 (en)	2009-09-01	2009-10-07	King S College London	Therapeutic compounds and their use
WO2012028100A1 (en) *	2010-09-01	2012-03-08	Glaxo Group Limited	Novel compounds
US10647688B2 (en) *	2014-12-19	2020-05-12	Galderma Research & Development	Compounds, synthesis method thereof and use of same in medicine and in cosmetics
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
US10865793B2 (en)	2016-12-06	2020-12-15	Air Squared, Inc.	Scroll type device having liquid cooling through idler shafts
US20200025199A1 (en)	2018-07-17	2020-01-23	Air Squared, Inc.	Dual drive co-rotating spinning scroll compressor or expander
US11530703B2 (en)	2018-07-18	2022-12-20	Air Squared, Inc.	Orbiting scroll device lubrication
US11473572B2 (en)	2019-06-25	2022-10-18	Air Squared, Inc.	Aftercooler for cooling compressed working fluid
US11898557B2 (en)	2020-11-30	2024-02-13	Air Squared, Inc.	Liquid cooling of a scroll type compressor with liquid supply through the crankshaft
US11885328B2 (en)	2021-07-19	2024-01-30	Air Squared, Inc.	Scroll device with an integrated cooling loop

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4001420A (en) *	1968-12-12	1977-01-04	Science Union Et Cie, Societe Francaise De Recherche Medical	Thiazolyl benzoic acid compounds
GB1308028A (en)	1970-06-12	1973-02-21	Science Union & Cie	Thiazolylbenzoic acid derivatives and a process for their manufactur
JPS4932853A (id)	1972-07-27	1974-03-26
US4043973A (en) *	1974-10-02	1977-08-23	Eastman Kodak Company	Multichromophoric ultraviolet stabilizers for organic compositions
US3939115A (en)	1974-10-02	1976-02-17	Eastman Kodak Company	Polychromophoric ultraviolet stabilizers and their use in organic compositions
US4164480A (en) *	1978-01-09	1979-08-14	Eastman Kodak Company	Polychromophoric ultraviolet stabilizers and their use in organic compositions
SU1078859A1 (ru)	1982-03-31	1997-10-20	Б.М. Красовицкий	2-(5-фенилоксазолил-2)-5-(5-арилоксазолил-2)-бензойные кислоты в качестве органических люминофоров сине-зеленого свечения в органических растворителях и водной среде
JPH0725754B2 (ja) *	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
JP2524786B2 (ja)	1987-12-15	1996-08-14	コニカ株式会社	直接ポジハロゲン化銀カラ―写真感光材料
DE3903993A1 (de)	1989-02-10	1990-08-16	Basf Ag	Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
JP2941937B2 (ja)	1990-01-25	1999-08-30	キヤノン株式会社	新規化合物、これを含む液晶組成物及びこれを使用した液晶素子並びに表示装置
JPH04154773A (ja) *	1990-10-15	1992-05-27	Green Cross Corp:The	チアゾール誘導体
DK0513387T3 (da)	1990-11-30	2000-06-05	Otsuka Pharma Co Ltd	Thiazolderivater som inhibitorer af aktivt oxygen
US5639770A (en)	1992-05-29	1997-06-17	Otsuka Pharmaceutical Co., Ltd.	Thiazole derivatives
JP3385387B2 (ja)	1992-05-29	2003-03-10	大塚製薬株式会社	チアゾール誘導体
US5342851A (en)	1992-10-07	1994-08-30	Mcneil-Ppc, Inc.	Substituted thiazole derivatives useful as platelet aggregation inhibitors
DE4302051A1 (de)	1993-01-26	1994-07-28	Thomae Gmbh Dr K	5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR19980702466A (ko)	1995-02-24	1998-07-15	페라 스타르크, 요헨 카르크	피라졸-4-일-벤조일 유도체 및 제초제로서의 그의 용도
JP3964478B2 (ja) *	1995-06-30	2007-08-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JP3865829B2 (ja)	1995-09-21	2007-01-10	株式会社医薬分子設計研究所	レチノイド作用増強性化合物
ES2124167B1 (es)	1996-06-04	1999-09-16	Espanola Prod Quimicos	Nuevos derivados del bencimidazol con actividad antihistaminica.
AU4015497A (en) *	1996-08-26	1998-03-19	Byk Gulden Lomberg Chemische Fabrik Gmbh	Thiazole derivatives useful as selective inhibitors of pde-iv
JP4300373B2 (ja)	1996-09-30	2009-07-22	大塚製薬株式会社	サイトカイン産生抑制剤及び接着抑制剤
AUPO691897A0 (en)	1997-05-21	1997-06-12	Fujisawa Pharmaceutical Co., Ltd.	New compound

1999
- 1999-06-30 WO PCT/JP1999/003520 patent/WO2000001679A1/ja not_active Ceased
- 1999-06-30 ID IDW20010004D patent/ID29247A/id unknown
- 1999-06-30 CA CA002332178A patent/CA2332178A1/en not_active Abandoned
- 1999-06-30 KR KR1020007014995A patent/KR20010053282A/ko not_active Withdrawn
- 1999-06-30 PL PL99345247A patent/PL345247A1/xx not_active Application Discontinuation
- 1999-06-30 BR BR9911752-5A patent/BR9911752A/pt not_active Application Discontinuation
- 1999-06-30 CN CN99810103A patent/CN1314899A/zh active Pending
- 1999-06-30 IL IL14042299A patent/IL140422A0/xx unknown
- 1999-06-30 AU AU43947/99A patent/AU4394799A/en not_active Abandoned
- 1999-06-30 EP EP99926853A patent/EP1092711A4/en not_active Withdrawn
- 1999-06-30 HU HU0102470A patent/HUP0102470A3/hu unknown
- 1999-06-30 US US09/720,644 patent/US6545009B1/en not_active Expired - Fee Related
- 1999-06-30 SK SK2018-2000A patent/SK20182000A3/sk unknown
2000
- 2000-12-19 ZA ZA200007635A patent/ZA200007635B/en unknown
- 2000-12-27 NO NO20006667A patent/NO20006667L/no not_active Application Discontinuation
- 2000-12-28 LV LVP-00-177A patent/LV12633B/en unknown

Also Published As

Publication number	Publication date
US6545009B1 (en)	2003-04-08
EP1092711A4 (en)	2002-07-31
AU4394799A (en)	2000-01-24
SK20182000A3 (sk)	2001-08-06
PL345247A1 (en)	2001-12-03
WO2000001679A1 (en)	2000-01-13
KR20010053282A (ko)	2001-06-25
IL140422A0 (en)	2002-02-10
CN1314899A (zh)	2001-09-26
NO20006667D0 (no)	2000-12-27
BR9911752A (pt)	2001-04-03
LV12633A (lv)	2001-03-20
HUP0102470A2 (hu)	2002-04-29
HUP0102470A3 (en)	2002-05-28
CA2332178A1 (en)	2000-01-13
ID29247A (id)	2001-08-16
EP1092711A1 (en)	2001-04-18
LV12633B (en)	2001-07-20
ZA200007635B (en)	2002-01-02

Legal Events

Date	Code	Title	Description
2003-02-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
Cordeiro et al.	2020	Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles
Easmon et al.	2006	Synthesis, structure− activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics
Hasegawa et al.	2014	Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists
AU2004276252B2 (en)	2007-11-22	Therapeutic agents useful for treating pain
Tasaka et al.	2001	Synthesis and structure–activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance
Ishikawa et al.	2009	Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators
ATE303387T1 (de)	2005-09-15	Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
TNSN06315A1 (en)	2007-12-03	Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
Hunt et al.	2012	Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat
Tanaka et al.	2004	Synthesis of anilino-monoindolylmaleimides as potent and selective PKCβ inhibitors
Asaki et al.	2006	Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
Sriram et al.	2004	Antituberculous activity of some aryl semicarbazone derivatives
van Hes et al.	2003	SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition
Lee et al.	2012	Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3β inhibitors
Gaykar et al.	2022	Synthesis of Trisubstituted Oxazoles via Aryne Induced [2, 3] Sigmatropic Rearrangement–Annulation Cascade
NO20065122L (no)	2006-11-07	1,1'-(1,2-etyndiyl)bis-benzenderivater som PTP 1-B-hemmere
CA2701853A1 (en)	2009-04-16	Metabotropic glutamate receptor modulators for the treatment of parkinson's disease
Fang et al.	2018	Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors
Papeo et al.	2005	A new glycociamidine ring precursor: Syntheses of (Z)-hymenialdisine,(Z)-2-debromohymenialdisine, and (±)-endo-2-debromohymenialdisine
Bennett et al.	2012	Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain
Vachal et al.	2006	Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor
Suryadevara et al.	2013	Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents
Sweeney et al.	2008	Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase
Jha et al.	2025	Photoinduced cascade synthesis of oxindoles and isoquinolinediones
NO20081220L (no)	2008-05-08	Nytt cercosporamidderivat